EGFR and colorectal carcinoma: In addition, cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), is found to promote ferroptosis induced by RSL3 via suppressing Nrf2/HO-1 signal pathway in KRAS mutant CRC cells, which was lately confirmed in a nude mouse model [75,76].